CN113116852A - Nicergoline orally disintegrating tablet - Google Patents
Nicergoline orally disintegrating tablet Download PDFInfo
- Publication number
- CN113116852A CN113116852A CN202110370747.6A CN202110370747A CN113116852A CN 113116852 A CN113116852 A CN 113116852A CN 202110370747 A CN202110370747 A CN 202110370747A CN 113116852 A CN113116852 A CN 113116852A
- Authority
- CN
- China
- Prior art keywords
- nicergoline
- orally disintegrating
- disintegrating tablet
- crospovidone
- croscarmellose sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
Abstract
The application provides a nicergoline orally disintegrating tablet which is stable and has good disintegrating effect, wherein microcrystalline cellulose and mannitol are used as filling agents, and crospovidone and dry starch which can be selected from croscarmellose sodium are used as disintegrating agents. The orally disintegrating tablet is prepared by a direct tabletting method, the process is simple, the quality uniformity is easy to control, and the prepared orally disintegrating tablet realizes good unification of stability and dissolution performance.
Description
Technical Field
The application provides a nicergoline orally disintegrating tablet which is stable and has good disintegrating effect, wherein microcrystalline cellulose and mannitol are used as filling agents, and crospovidone and dry starch which can be selected from croscarmellose sodium are used as disintegrating agents.
Background
The application belongs to the field of medicaments and the field of nervous system disease medicaments, and particularly provides a nicergoline orally disintegrating tablet which is stable and has a good disintegrating effect.
Nicergoline (Nicergolent) is a semisynthetic ergoline derivative with α -receptor blocking and vasodilating effects of mefenoxate. Nicergoline can enhance energy metabolism of nerve cells, promote biosynthesis of brain protein, and promote conversion of neurotransmitter dopamine to increase nerve conduction, thereby realizing repair of neuron function and improving symptoms of brain function damage and brain deterioration.
Nicergoline is widely used for treating headache, cerebrovascular diseases, brain dysfunction, Alzheimer disease and other diseases at home and abroad, and the commercial dosage forms comprise enteric-coated tablets, sustained-release granules, capsules, injections and the like. Although research and report are reported at home and abroad as an orally disintegrating tablet formulation which is most convenient to use and has high bioavailability, no product is on the market so far. The main reason is that nicergoline is sensitive to high temperature and high humidity and has poor compatibility with various hygroscopic disintegrants such as sodium carboxymethyl starch, namely a certain contradiction exists between disintegration performance and drug stability of nicergoline tablets (not limited to orally disintegrating tablets), and the relationship between the nicergoline tablets and the drug stability is difficult to balance under the condition that the orally disintegrating dosage form is limited more.
Disclosure of Invention
Based on the previous research on nicergoline orally disintegrating tablets, the applicant tries to use a new combination of a filler and a disintegrant to construct a nicergoline orally disintegrating tablet with simple component and preparation process and low cost, and finds that the combination of the disintegrant of crospovidone and croscarmellose sodium can provide good disintegration and good stability balance, and the disintegration can be further improved by further adding dry starch.
In one aspect, the application provides an orally disintegrating tablet of nicergoline, comprising 3-10g of nicergoline, 40-80g of filler and 2-5g of disintegrant per 1000 tablets, wherein the disintegrant is selected from crospovidone, croscarmellose sodium and dry starch.
Furthermore, the nicergoline orally disintegrating tablet also comprises 2-4g of effervescent agent and 0.1-1g of lubricant per 1000 tablets; preferably, the effervescent agent is 2g of citric acid, 1.5g of sodium bicarbonate and the lubricant is 0.3g of magnesium stearate.
Further, the filler is 15g of microcrystalline cellulose and 35g of mannitol.
Further, the disintegrant is crospovidone and croscarmellose sodium.
Further, the disintegrant is crospovidone 2g and croscarmellose sodium 2 g.
Further, the disintegrant is crospovidone, croscarmellose sodium and dry starch.
Further, the disintegrating agent comprises 2g of crospovidone, 2g of croscarmellose sodium and 0.5g of dry starch
Further, the nicergoline orally disintegrating tablet is prepared by a direct compression method.
In another aspect, the application provides the use of crospovidone, croscarmellose sodium and dry starch as disintegrants in the preparation of an orally disintegrating tablet of nicergoline.
Further, the weight ratio of croscarmellose sodium to dry starch is 4: 4: 1.
the nicergoline can be purchased in the market or prepared by the user, and various auxiliary materials can be selected from products of various manufacturers according with relevant standards.
The orally disintegrating tablet is prepared by a direct tabletting method, the process is simple, the quality uniformity is easy to control, and the prepared orally disintegrating tablet realizes good unification of stability and dissolution performance and has potential of practical marketing.
Drawings
FIG. 1: dissolution results for 6 formulations are shown schematically.
Detailed Description
Main reagents and instruments:
rotary tablet presses (fly, XYP-9B);
tablet hardometer (BIOBASE, YD-2);
drug dissolution apparatus (Chuangxing, RC12 DF);
disintegration apparatus (Chuangxing, BJ-3);
liquid chromatography (shimadzu, LC 2030);
nicergoline raw material medicine: the applicant self-manufactures and meets related standards (identification and structure in melting point, thermal analysis, element analysis, spectrum and mass spectrum methods, and considers the quality in aspects of appearance, solubility, absorption, optical rotation, impurities, drying weight loss and the like);
and (3) standard substance: check in purchases
Microcrystalline cellulose: xian jin-sourced Biotechnology Ltd;
mannitol: shijiazhuang Huaxing pharmaceutical factory;
crospovidone: basf;
citric acid: shijiazhuang Huaxing pharmaceutical factory;
sodium bicarbonate: shijiazhuang Huaxing pharmaceutical factory;
lactose (amorphous): shanxi brocade medicinal adjuvant Co., Ltd;
dry starch: shanxi brocade medicinal adjuvant Co., Ltd;
croscarmellose sodium: shijiazhuang Huaxing pharmaceutical factory;
chromatographic grade acetonitrile: DIKMA
Other unexhausted reagents are of the domestic conventional variety.
EXAMPLE 1 part of the formulation List
The listed formulas are only part of representative formulas, and a large number of other formulas involved in the screening process are not shown one by one due to space, representativeness and the like.
The following formulation is a 9mm tablet by direct compression, with a hardness of 4kg, based on 1000 tablets:
formula 1:
5g of nicergoline, 15g of microcrystalline cellulose, 35g of mannitol, 3g of crospovidone, 2g of citric acid, 1.5g of sodium bicarbonate and 0.5g of magnesium stearate;
and (2) formula:
5g of nicergoline, 10g of microcrystalline cellulose, 10g of non-crystalline lactose, 30g of mannitol, 3g of crospovidone, 2g of citric acid, 1.5g of sodium bicarbonate and 0.3g of magnesium stearate;
and (3) formula:
5g of nicergoline, 20g of microcrystalline cellulose, 30g of mannitol, 2g of crospovidone, 2g of croscarmellose sodium, 2g of citric acid, 1.5g of sodium bicarbonate and 0.5g of magnesium stearate;
and (4) formula:
5g of nicergoline, 20g of microcrystalline cellulose, 30g of mannitol, 2g of crospovidone, 2g of croscarmellose sodium, 0.5g of dry starch, 2g of citric acid, 1.5g of sodium bicarbonate and 0.5g of magnesium stearate;
and (5) formula:
5g of nicergoline, 20g of microcrystalline cellulose, 30g of mannitol, 2g of crospovidone, 2g of croscarmellose sodium, 1g of dry starch, 2g of citric acid, 1.5g of sodium bicarbonate and 0.3g of magnesium stearate;
and (6) formula:
5g of nicergoline, 20g of microcrystalline cellulose, 30g of mannitol, 2.5g of croscarmellose sodium, 1.5g of dry starch, 2g of citric acid, 1.5g of sodium bicarbonate and 0.3g of magnesium stearate.
Example 2 disintegration and stability testing
And (3) testing the disintegration property:
5 pieces of the detection tablet are placed in a hanging basket of the disintegration tester, and the disintegration tester is started to record the average disintegration time. The results are as follows:
according to the detection result of the disintegration tester, the 6 formulas can basically meet the requirements; in the test of volunteer reagent buccal administration, the disintegration time recorded by volunteers is generally prolonged by about 1.5-2 times, and according to experience, the formula 1-4 can meet the actual use requirement by matching with a proper flavoring agent.
And (3) stability detection:
the tablets were taken in multiple tablets, without packaging, protected from light in a constant temperature (25 ℃) and humidity (40%) environment, and the impurity contents were recorded on days 0, 3, 7 and 14 (since the formulations were large, the curves were difficult to distinguish in one graph, and the representative results on day 7 are shown in the table below).
Tablet 1 (i.e. nicergoline 5mg) powder was dissolved in 25mL acetonitrile with ultrasonic assistance. The initial state of the tablet solution was used as a control, the chromatographic parameters were adjusted, and the impurity peak and main peak areas were recorded.
Formulation of | Maximum single impurity (%) | Total impurities (%) |
|
0.91±0.07 | 2.06±0.13 |
|
1.05±0.15 | 1.37±0.17 |
|
0.82±0.07 | 1.22±0.22 |
|
0.22±0.04 | 0.38±0.08 |
|
0.24±0.08 | 0.56±0.01 |
|
0.77±0.06 | 0.99±0.11 |
After 14 days, the appearance of each tablet is not obviously changed, and the hardness is slightly reduced. In the aspect of impurities, the effects of the formulas 1-3 and 6 are not ideal and are close to or exceed the standard limit of 1% or 2%, and according to experience and subsequent packaging experiments, the stability cannot meet the preservation requirement of more than 1 year by adopting a conventional packaging form with lower price. The combination of crospovidone, croscarmellose sodium, and dry starch may provide suitable preservation properties.
Example 3 dissolution Performance testing
Dissolution test:
adopting a paddle method, taking 500mL of 0.1M HCl as a dissolution medium, and carrying out the steps at 100r/min and 37 ℃; 10mL of the solution was tested at 2, 4, 6, 10, 15, 20, 30 minutes and supplemented with an equal amount of fresh medium. The standard substance is prepared into a standard solution of 20 ug/mL. The two solutions were removed and the absorbance at 288nm was measured by spectrophotometry, and the elution amount and the cumulative elution rate were calculated (see the 2010 pharmacopoeia).
The results of the dissolution results of the 6 formulations are shown in fig. 1, and show that the dissolution effects of the formulations other than formulation 6 are similar, and 90% is obtained in 10 minutes, and that formulation 2 using lactose for dissolution is slightly better, and formulations 5 and 6 having poor disintegration properties are slightly worse.
Claims (10)
1. The nicergoline orally disintegrating tablet is characterized in that each 1000 tablets contain nicergoline 3-10g, a filling agent 40-80g and a disintegrating agent 2-5g, wherein the disintegrating agent is selected from crospovidone, croscarmellose sodium and dry starch.
2. The nicergoline orally disintegrating tablet of claim 1, further comprising 2-4g of effervescent agent and 0.1-1g of lubricant per 1000 tablets; preferably, the effervescent agent is 2g of citric acid, 1.5g of sodium bicarbonate and the lubricant is 0.3g of magnesium stearate.
3. The nicergoline orally disintegrating tablet of claim 1 or 2, wherein the filler is microcrystalline cellulose 15g and mannitol 35 g.
4. The nicergoline orally disintegrating tablet of any one of claims 1-3, wherein the disintegrant is crospovidone and croscarmellose sodium.
5. The nicergoline orally disintegrating tablet of claim 4, wherein the disintegrant is crospovidone 2g and croscarmellose sodium 2 g.
6. The nicergoline orally disintegrating tablet of any one of claims 1-3, wherein the disintegrant is crospovidone, croscarmellose sodium and dry starch.
7. The nicergoline orally disintegrating tablet of claim 6, wherein the disintegrant is crospovidone 2g, croscarmellose sodium 2g, and dry starch 0.5 g.
8. The nicergoline orally disintegrating tablet of any one of claims 1-7, prepared using a direct compression method.
9. Application of crospovidone, croscarmellose sodium and dry starch as disintegrant in preparing nicergoline orally disintegrating tablet is provided.
10. The use according to claim 9, wherein the weight ratio of crospovidone, croscarmellose sodium and dry starch is 4: 4: 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110370747.6A CN113116852B (en) | 2021-04-07 | 2021-04-07 | Nicergoline orally disintegrating tablet |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110370747.6A CN113116852B (en) | 2021-04-07 | 2021-04-07 | Nicergoline orally disintegrating tablet |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113116852A true CN113116852A (en) | 2021-07-16 |
CN113116852B CN113116852B (en) | 2022-10-21 |
Family
ID=76775123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110370747.6A Active CN113116852B (en) | 2021-04-07 | 2021-04-07 | Nicergoline orally disintegrating tablet |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113116852B (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0624987A (en) * | 1992-07-09 | 1994-02-01 | Tanabe Seiyaku Co Ltd | Nicergolin-containing tablet |
JP2983973B1 (en) * | 1998-10-13 | 1999-11-29 | 大正薬品工業株式会社 | Oral fast disintegrating solid preparation |
JP2001354566A (en) * | 2000-06-16 | 2001-12-25 | Ohara Yakuhin Kogyo Kk | Tablet of nicergoline |
CN1589796A (en) * | 2004-06-10 | 2005-03-09 | 范敏华 | Nicergoline oral cavity disintegration tablet and its preparation method |
CN101711749A (en) * | 2009-12-24 | 2010-05-26 | 南昌弘益科技有限公司 | Nicergoline sublingual tablet and preparation method thereof |
US20110229570A1 (en) * | 2008-11-25 | 2011-09-22 | Masaaki Sugimoto | Orally rapidly disintegrating tablet and process for producing same |
US20120156261A1 (en) * | 2009-08-11 | 2012-06-21 | Keiichi Fujiwara | Disintegrating particle composition and orally rapidly disintegrating tablet |
US20130274297A1 (en) * | 2010-12-22 | 2013-10-17 | Aptalis Pharma Limited | Pharmaceutical composites of poorly water soluble drugs and polymers |
CN103656654A (en) * | 2013-12-10 | 2014-03-26 | 天津科技大学 | Instant orally-disintegrating tablet and its preparation method |
US20170112762A1 (en) * | 2014-06-10 | 2017-04-27 | Capsugel Belgium Nv | Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use |
US20180280304A1 (en) * | 2015-10-05 | 2018-10-04 | Daido Chemical Corporation | Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing composite granulated product |
-
2021
- 2021-04-07 CN CN202110370747.6A patent/CN113116852B/en active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0624987A (en) * | 1992-07-09 | 1994-02-01 | Tanabe Seiyaku Co Ltd | Nicergolin-containing tablet |
JP2983973B1 (en) * | 1998-10-13 | 1999-11-29 | 大正薬品工業株式会社 | Oral fast disintegrating solid preparation |
JP2001354566A (en) * | 2000-06-16 | 2001-12-25 | Ohara Yakuhin Kogyo Kk | Tablet of nicergoline |
CN1589796A (en) * | 2004-06-10 | 2005-03-09 | 范敏华 | Nicergoline oral cavity disintegration tablet and its preparation method |
CN102223880A (en) * | 2008-11-25 | 2011-10-19 | 田边三菱制药株式会社 | Orally rapidly disintegrating tablet, and process for producing same |
US20110229570A1 (en) * | 2008-11-25 | 2011-09-22 | Masaaki Sugimoto | Orally rapidly disintegrating tablet and process for producing same |
CN103919742A (en) * | 2008-11-25 | 2014-07-16 | 田边三菱制药株式会社 | Orally Rapidly Disintegrating Tablet And Process For Producing Same |
US20120156261A1 (en) * | 2009-08-11 | 2012-06-21 | Keiichi Fujiwara | Disintegrating particle composition and orally rapidly disintegrating tablet |
CN101711749A (en) * | 2009-12-24 | 2010-05-26 | 南昌弘益科技有限公司 | Nicergoline sublingual tablet and preparation method thereof |
US20130274297A1 (en) * | 2010-12-22 | 2013-10-17 | Aptalis Pharma Limited | Pharmaceutical composites of poorly water soluble drugs and polymers |
CN103656654A (en) * | 2013-12-10 | 2014-03-26 | 天津科技大学 | Instant orally-disintegrating tablet and its preparation method |
US20170112762A1 (en) * | 2014-06-10 | 2017-04-27 | Capsugel Belgium Nv | Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use |
US20180280304A1 (en) * | 2015-10-05 | 2018-10-04 | Daido Chemical Corporation | Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing composite granulated product |
Non-Patent Citations (3)
Title |
---|
孙冠男等: "可用于口腔崩解片的新型崩解剂研究概况", 《中国药房》 * |
彭红等: "尼麦角林口腔崩解片的研制", 《江西中医学院学报》 * |
赵弘泰: "直接压片法制备口腔崩解片预混辅料的研制", 《中国优秀博硕士学位论文全文数据库(硕士)(医药卫生科技辑)》 * |
Also Published As
Publication number | Publication date |
---|---|
CN113116852B (en) | 2022-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2684977C (en) | A method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant | |
US20080008752A1 (en) | Pharmaceutical compositions of memantine | |
EP2939662A1 (en) | Pharmaceutical composition with improved stability, containing temozolomide, and preparation method therefor | |
CN108272765B (en) | Pharmaceutical composition containing vardenafil hydrochloride, orally disintegrating tablet, and preparation and application thereof | |
CN101244044B (en) | Entecavir dispersible tablet and preparation thereof | |
AU2010274589A1 (en) | Oral pharmaceutical composition of rasagiline and process for preparing thereof | |
CN105412036A (en) | Brexpiprazole orally disintegrating tablets | |
CA2744211A1 (en) | Wet granulation of tenofovir, emtricitabine and efavirenz | |
EP2612659A1 (en) | Panaxatriol saponins enteric pellet, capsule comprising same and method for preparing same | |
CN113116852B (en) | Nicergoline orally disintegrating tablet | |
CN105560199B (en) | A kind of children's domperidone oral disintegrating tablet and preparation method thereof | |
CA2998982A1 (en) | Pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof | |
CN106018618B (en) | Escitalopram oxalate tablet composition and quality control method | |
CN109908104B (en) | Amoxicillin capsule and preparation method thereof | |
JP2017052752A (en) | Pharmaceutical composition containing irbesartan, and production method of the same | |
KR100780479B1 (en) | Oral drug comprising Ibudilast and manufacturing method | |
JP7153197B2 (en) | Tableted pharmaceutical composition containing nalfurafine | |
CN102268042A (en) | Minodronate crystalform II and preparation method thereof | |
US9271951B2 (en) | Levothyroxine formulation with acacia | |
JP2022130003A (en) | Solid preparation containing chinese medicine extract or vegetable herbal medicine extract, and method for producing the same, and method for improving the ease of disintegration of solid preparation | |
Ragade et al. | Formulation and Evaluation of Candesartan Cilexetil Mouth Dissolving Tablet by using Natural Superdisintegrant | |
CN101460191A (en) | Stable formulation comprising moisture sensitive drugs and manufacturing procedure thereof | |
JP2012180280A (en) | Solid preparation having improved storage stability | |
CN117338733B (en) | Tenofovir disoproxil fumarate tablet and preparation process thereof | |
CN112618503B (en) | Cefdinir dispersible tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |